Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00418886
Registration number
NCT00418886
Ethics application status
Date submitted
4/01/2007
Date registered
5/01/2007
Date last updated
28/09/2023
Titles & IDs
Public title
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
Query!
Scientific title
A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination With Pemetrexed (Alimta®) Versus Pemetrexed Alone in Patients With Locally-Advanced or Metastatic NSCLC
Query!
Secondary ID [1]
0
0
EUDRACT No. 2006-003695-35
Query!
Secondary ID [2]
0
0
D4200C00036
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ZEAL
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non Small Cell Lung Cancer
0
0
Query!
Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Vandetanib
Treatment: Drugs - Pemetrexed
Placebo comparator: 1 - Placebo Vandetanib + Pemetrexed
Experimental: 2 - Vandetanib + Pemetrexed
Treatment: Drugs: Vandetanib
oral once daily tablet
Treatment: Drugs: Pemetrexed
intravenous infusion
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-Free Survival (PFS) in the Overall Population
Query!
Assessment method [1]
0
0
Median time (in weeks) from randomisation until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment
Query!
Timepoint [1]
0
0
RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomisation until objective progression
Query!
Primary outcome [2]
0
0
Progression-Free Survival (PFS) in the Female Population
Query!
Assessment method [2]
0
0
Median time (in weeks) from randomisation until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment
Query!
Timepoint [2]
0
0
RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomisation until objective progression
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
Overall survival is defined as the time from date of randomization until death. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive (ie their status must be known at the censored date and should not be lost to follow up or unknown).
Query!
Timepoint [1]
0
0
Time to death in months
Query!
Secondary outcome [2]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [2]
0
0
The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) as defined by RECIST criteria.
The categories for best objective response are CR, PR, stable disease (SD)\>= 6 weeks, progressive disease (PD) or NE.
Query!
Timepoint [2]
0
0
Each patient was assessed for objective response from the sequence of RECIST scan data up to data cut off. RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomisation until objective progression
Query!
Secondary outcome [3]
0
0
Disease Control Rate (DCR)
Query!
Assessment method [3]
0
0
Disease control rate is defined as the number of patients who achieved disease control at 6 weeks following randomisation. Disease control at 6 weeks is defined as a best objective response of complete response (CR), partial response (PR) or stable disease (SD) \>= 6 weeks
Query!
Timepoint [3]
0
0
RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomisation until objective progression
Query!
Secondary outcome [4]
0
0
Duration of Response (DoR)
Query!
Assessment method [4]
0
0
Response is defined as a confirmed best objective response of CR or PR. Duration of response is defined as time from the date of first documented response until date of documented progression or death in the absence of disease progression (provided death is within 3 months of last RECIST assessment)
Query!
Timepoint [4]
0
0
RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomisation until objective progression
Query!
Secondary outcome [5]
0
0
Time to Deterioration of Disease-related Symptoms (TDS) by Lung Cancer Symptom Scale (LCSS) Total Score
Query!
Assessment method [5]
0
0
TDS is the interval from the date of randomization to the first assessment of worsened without an improvement in the next 21 days. A deterioration in symptoms is defined as a single visit assessment of 'worsened' with no visit assessment of 'improved' within the next 21 days. The LCSS scale measures changes in symptoms associated with lung cancer.
Query!
Timepoint [5]
0
0
LCSS questionnaires are to be administered every 3 weeks after randomisation
Query!
Secondary outcome [6]
0
0
Time to Deterioration of Disease-related Symptoms (TDS) by Average Symptom Burden Index (ASBI) Score
Query!
Assessment method [6]
0
0
Time to deterioration is defined as the interval from the date of randomization to the first assessment of worsened without an improvement in the next 21 days. A deterioration in symptoms is defined as a single visit assessment of 'worsened' with no visit assessment of 'improved' within the next 21 days. The ASBI is derived from 6 of LCSS's 9 items
Query!
Timepoint [6]
0
0
ASBI is a score taken from the LCSS questionnaires which are to be administered every 3 weeks after randomisation
Query!
Secondary outcome [7]
0
0
Longitudinal Analysis of Lung Cancer Symptom Scale (LCSS) Total Score
Query!
Assessment method [7]
0
0
The longitudinal data analysis will include all non-missing visit scores and the model will include only the first 12 weeks of data. LCSS total score is an average of all nine visual analogue patient scales from "none" (0 mm) to "as much as it could be" (100 mm)
Query!
Timepoint [7]
0
0
LCSS questionnaires are to be administered every 3 weeks after randomisation
Query!
Secondary outcome [8]
0
0
Longitudinal Analysis of Average Symptom Burden Index (ASBI) Score
Query!
Assessment method [8]
0
0
The longitudinal data analysis will include all non-missing visit scores and the model will include only the first 12 weeks of data. ASBI is an average of the six symptom visual analogue patient scales from "none" (0 mm) to "as much as it could be" (100 mm).
Query!
Timepoint [8]
0
0
ASBI is a score taken from the Lung Cancer Symptom Scale (LCSS) questionnaires administered every 3 weeks after randomisation
Query!
Eligibility
Key inclusion criteria
* Provision of informed consent
* Female or male aged 18 years or above
* Histologic or cytologic confirmation of locally advanced or metastatic NSCLC (stage IIIB or IV) on entry into study
* Failure of 1st line anti-cancer therapy (either radiological documentation of disease progression or due to toxicity) or subsequent relapse of disease following 1st line therapy
* WHO Performance status 0 - 2
* One or more measurable lesions at least 10 mm in the longest diameter (LD) by spiral CT scan or 20 mm with conventional techniques according to RECIST criteria. Previously irradiated lesions will not be considered measurable.
* Life expectancy of 12 weeks or longer
* Negative pregnancy test for women of childbearing potential only
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Mixed small cell and non-small cell lung cancer histology
* Patients have received 2nd-line or subsequent anti-cancer therapy
* Prior treatment with pemetrexed
* Prior treatment with VEGFR TKIs (previous treatment with bevacizumab [Avastin] is permitted)
* Known or suspected brain metastases or spinal cord compression, unless treated at least 4 weeks before entry, and stable without steroid treatment for 10 days
* The last radiation therapy within 4 weeks before the start of study therapy, not including local palliative radiation
* The last dose of prior chemotherapy or other anti-cancer therapy is discontinued less than 3 weeks before the start of study therapy (6 weeks for nitrosoureas, mitomycin, and suramin)
* Major surgery within 4 weeks before entry, or incompletely healed surgical incision
* Neutrophils <1.5 x 109/L or platelets <100 x 109/L
* Serum bilirubin >1.5 x the upper limit of reference range (ULRR)
* Creatinine clearance <50 ml/min calculated by either Cockcroft -Gault, 24 hours urine collection, EDTA scan or other validated methods
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 x ULRR in the absence of liver metastases, or > 5 x ULRR in the presence of liver metastases
* Alkaline phosphatase (ALP) >2.5 x ULRR in the absence of liver metastases, or >5 x ULRR in the presence of liver metastases
* Current active gastrointestinal disease that may affect the ability of the patient to absorb ZD6474 or tolerate diarrhoea
* Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol
* Any unresolved toxicity greater than CTCAE Grade 2 from previous anti-cancer therapy
* Significant cardiovascular event (e.g., myocardial infarction, superior vena cava [SVC] syndrome), New York Heart Association [NYHA] classification of heart disease =2 within 3 months before entry, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia
* History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled on medication is not excluded
* Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age
* QT prolongation with other medications that required discontinuation of that medication
* Presence of left bundle branch block (LBBB)
* QTc with Bazett's correction unmeasurable or = 480 msec on screening ECG (Note: If a patient has QTc interval =480 msec on screening ECG, the screen ECG may be repeated twice [at least 24 hours apart]. The average QTc from the three screening ECGs must be <480 msec in order for the patient to be eligible for the study) Patients who are receiving a drug that has a risk of QTc prolongation are eligible if QTc is <460 msec.
* Potassium <4.0 mmol/L despite supplementation; serum calcium (or ionized or adjusted for albumin), or magnesium out of normal range despite supplementation
* Women who are pregnant or breast-feeding
* Any concomitant medications that may cause QTc prolongation or induce Torsades de Pointes or induce CYP3A4 function. Drugs that have a risk of QTc prolongation, that in the investigator's opinion cannot be discontinued, are allowed, but only of the QTc is <460 msec
* Hypertension not controlled by medical therapy (systolic blood pressure greater than 160 millimetre of mercury [mmHg] or diastolic blood pressure greater than 100 mmHg)
* Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix and adequately treated basal cell or squamous cell carcinoma of the skin
* Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment
* Concomitant use of yellow fever vaccine or any live attenuated vaccines
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
14/02/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
698
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Chermside
Query!
Recruitment hospital [2]
0
0
Research Site - Fitzroy
Query!
Recruitment hospital [3]
0
0
Research Site - Footscray
Query!
Recruitment hospital [4]
0
0
Research Site - Heidelberg
Query!
Recruitment hospital [5]
0
0
Research Site - Randwick
Query!
Recruitment hospital [6]
0
0
Research Site - St. Leonards
Query!
Recruitment hospital [7]
0
0
Research Site - Wodonga
Query!
Recruitment postcode(s) [1]
0
0
- Chermside
Query!
Recruitment postcode(s) [2]
0
0
- Fitzroy
Query!
Recruitment postcode(s) [3]
0
0
- Footscray
Query!
Recruitment postcode(s) [4]
0
0
- Heidelberg
Query!
Recruitment postcode(s) [5]
0
0
- Randwick
Query!
Recruitment postcode(s) [6]
0
0
- St. Leonards
Query!
Recruitment postcode(s) [7]
0
0
- Wodonga
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
District of Columbia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Iowa
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maine
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Massachusetts
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
North Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Ohio
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
South Carolina
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Texas
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Utah
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Avellaneda
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Buenos Aires
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
Ciudad de Buenos Aires
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Córdoba
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
La Plata
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Ramos Mejía
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Salta
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
Santa Fe
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Brussels (Woluwé-St-Lambert)
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Leuven
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Liège
Query!
Country [30]
0
0
Colombia
Query!
State/province [30]
0
0
Bogota
Query!
Country [31]
0
0
Colombia
Query!
State/province [31]
0
0
Medellín
Query!
Country [32]
0
0
Colombia
Query!
State/province [32]
0
0
Pereira
Query!
Country [33]
0
0
Colombia
Query!
State/province [33]
0
0
Valledupar
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Avignon Cedex 09
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Lyon Cedex 04
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Paris Cedex 15
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Pontoise Cedex
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Strasbourg Cedex
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Hannover
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Karlsruhe
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Kassel
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Köln
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Leipzig
Query!
Country [44]
0
0
Greece
Query!
State/province [44]
0
0
N. Faliro
Query!
Country [45]
0
0
Greece
Query!
State/province [45]
0
0
Patras
Query!
Country [46]
0
0
Greece
Query!
State/province [46]
0
0
Thessaloniki
Query!
Country [47]
0
0
Hong Kong
Query!
State/province [47]
0
0
Hong Kong
Query!
Country [48]
0
0
India
Query!
State/province [48]
0
0
Ahmedabad
Query!
Country [49]
0
0
India
Query!
State/province [49]
0
0
Vellore
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Beer-Sheeva
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Haifa
Query!
Country [52]
0
0
Israel
Query!
State/province [52]
0
0
Jerusalem
Query!
Country [53]
0
0
Israel
Query!
State/province [53]
0
0
Kfar Saba
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Petach-Tikva
Query!
Country [55]
0
0
Israel
Query!
State/province [55]
0
0
Safed
Query!
Country [56]
0
0
Israel
Query!
State/province [56]
0
0
Tel-Hashomer
Query!
Country [57]
0
0
Israel
Query!
State/province [57]
0
0
Zerifin
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Genova
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Milano
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Orbassano
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Roma
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
S.Andrea Delle Fratte
Query!
Country [63]
0
0
Mexico
Query!
State/province [63]
0
0
Aguascalientes
Query!
Country [64]
0
0
Mexico
Query!
State/province [64]
0
0
Mexico
Query!
Country [65]
0
0
Mexico
Query!
State/province [65]
0
0
Puebla
Query!
Country [66]
0
0
Philippines
Query!
State/province [66]
0
0
Cebu City
Query!
Country [67]
0
0
Philippines
Query!
State/province [67]
0
0
Manila
Query!
Country [68]
0
0
Philippines
Query!
State/province [68]
0
0
Pasay City
Query!
Country [69]
0
0
Philippines
Query!
State/province [69]
0
0
Quezon City
Query!
Country [70]
0
0
Portugal
Query!
State/province [70]
0
0
Lisboa
Query!
Country [71]
0
0
Portugal
Query!
State/province [71]
0
0
Santa Maria da Feira
Query!
Country [72]
0
0
Portugal
Query!
State/province [72]
0
0
Setúbal
Query!
Country [73]
0
0
South Africa
Query!
State/province [73]
0
0
Cape Town
Query!
Country [74]
0
0
South Africa
Query!
State/province [74]
0
0
Durban
Query!
Country [75]
0
0
South Africa
Query!
State/province [75]
0
0
Johannesburg
Query!
Country [76]
0
0
South Africa
Query!
State/province [76]
0
0
Port Elizabeth
Query!
Country [77]
0
0
South Africa
Query!
State/province [77]
0
0
Pretoria
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
A Coruña
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Lugo
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
Majadahonda
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Mataró(Barcelona)
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Málaga
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Orense
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Santiago De Compostela(A Coru
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Vigo(Pontevedra)
Query!
Country [86]
0
0
Sweden
Query!
State/province [86]
0
0
Lund
Query!
Country [87]
0
0
Sweden
Query!
State/province [87]
0
0
Sundsvall
Query!
Country [88]
0
0
Sweden
Query!
State/province [88]
0
0
Umeå
Query!
Country [89]
0
0
Sweden
Query!
State/province [89]
0
0
Uppsala
Query!
Country [90]
0
0
Sweden
Query!
State/province [90]
0
0
Västerås
Query!
Country [91]
0
0
Taiwan
Query!
State/province [91]
0
0
Taipei
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Birmingham
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Edinburgh
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Leeds
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Manchester
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
Wolverhampton
Query!
Country [97]
0
0
Venezuela
Query!
State/province [97]
0
0
Caracas
Query!
Country [98]
0
0
Venezuela
Query!
State/province [98]
0
0
Valencia
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Genzyme, a Sanofi Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Non-small cell lung cancer (NSCLC) can be treated with drugs that kill tumour cells, stop them from dividing, or stop the growth of the blood supply that cancers need to grow and spread. Clinical research has shown that drugs that inhibit vascular endothelial growth factor receptor (VEGFR) or epidermal growth factor receptor (EGFR) signalling can increase overall survival in patients with advanced non-small cell lung cancer (NSCLC). Preclinical studies have shown that vandetanib (ZD6474) is an inhibitor of both VEGFR and EGFR signalling. Giving vandetanib may therefore inhibit the growth of cancer cells by blocking their blood supply and by stopping them from dividing. This lung cancer study is to investigate if adding vandetanib to Alimta (pemetrexed) is more effective than Alimta (pemetrexed) alone.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00418886
Query!
Trial related presentations / publications
de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, de Marinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J, Vansteenkiste JF. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2011 Mar 10;29(8):1067-74. doi: 10.1200/JCO.2010.29.5717. Epub 2011 Jan 31. Platt A, Morten J, Ji Q, Elvin P, Womack C, Su X, Donald E, Gray N, Read J, Bigley G, Blockley L, Cresswell C, Dale A, Davies A, Zhang T, Fan S, Fu H, Gladwin A, Harrod G, Stevens J, Williams V, Ye Q, Zheng L, de Boer R, Herbst RS, Lee JS, Vasselli J. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. BMC Cancer. 2015 Mar 23;15:171. doi: 10.1186/s12885-015-1146-8.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Sciences & Operations
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Type
Citations or Other Details
Journal
de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan ...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT00418886
Download to PDF